Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Apple Inc. | INDUSTRY |
| The International Organization of Multiple Sclerosis Nurses Inc | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems.
The study hypotheses include:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Virtual reality plus standard care (SC) then SC alone - randomized group | Experimental | Participants in this group are maintained on antidepressants or psychotherapy and will receive VR nature sessions alongside participants' current depression treatments. This will be followed by a 1-week washout period, after which they crossover to standard care only. |
|
| Standard care alone then Virtual reality plus SC- randomized group | Experimental | Participants in this group are maintained on standard depression treatments and will continue standard care for eight weeks. This will be followed by a 1-week washout period and crossover to VR plus Standard Care. |
|
| Virtual Reality - non-randomized group | Experimental | Participants that are not receiving any treatment for depression will receive VR nature sessions for 8 weeks without depression treatments for eight weeks followed by 1 week washout and 8 weeks of no VR. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Virtual Reality | Device | Participant will have 8 weeks of immersive VR nature-based experiences. Participants are expected to use the VR headset three times per week. Headsets will contain a prototype application (app) developed by Explore POV. This app will include approximately one hour of footage showcasing 15-25 different nature experiences, that will shuffle every time participants access it. Participants will have the option to choose between 5, 10, or 15 minutes, sessions while answering weekly surveys regarding their experiences. |
| Measure | Description | Time Frame |
|---|---|---|
| Changes to the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression short form 8b scores | This is an 8-item evaluating various aspects of depression, including negative mood, anhedonia, feelings of worthlessness, and cognitive impairments. Each item is rated on a 5-point Likert scale ranging from never (1) - always (5). Scores range from 8-40 with a higher score indicating greater symptom severity. | Baseline, 9-10 weeks and 20-21 weeks |
| Virtual Reality (VR) Sessions completed over 8 weeks | A benchmark of 70% will indicate adequate feasibility and acceptability. | 8-week VR intervention |
| Qualitative feedback on the VR Neuroscience Questionnaire during the intervention (groups 1 and 3) | The modified scale for this project uses 10 questions that participants will answer about the VR experience, rated from 1 (extremely low or extremely difficult) to 7 (extremely high or extremely easy). The scores range from 10 to 70, with higher scores indicating greater experience. A benchmark of 70% indicates adequate feasibility and acceptability, with participant satisfaction ratings above 80%. | 1-8 weeks (during VR) |
| Qualitative feedback with Semi-structured interviews for participants that received VR | Semi-structured interviews with 20 random participants (6-7 from each group) who received the VR treatment to capture participants' subjective experiences at the midpoint and end of the intervention. The interview questions will focus on emotional changes, engagement levels, and feedback on the intervention's implementation. | Weeks 9-10, Weeks 20- 21 |
| Enrollment rate | Feasibility will be assessed via enrollment. Recruitment will be quantified by enrollment rates relative to the number of eligibility screenings. |
| Measure | Description | Time Frame |
|---|---|---|
| Change to the PROMIS Anxiety short form scores of the VR experience | This consists of eight items assessing various dimensions of anxiety, including feelings of fear, worry, hyperarousal, and somatic symptoms. Each item is rated on a 5-point Likert scale ranging from never (1) - always (5). Scores range from 8-40 with a higher score indicating greater anxiety. | Baseline, 8 weeks (after VR) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Zee Petrie | Contact | 734- 764- 5249 | petrieli@umich.edu |
| Name | Affiliation | Role |
|---|---|---|
| Hala Darwish, PhD | University of Michigan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Michigan | Recruiting | Ann Arbor | Michigan | 48109 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020528 | Multiple Sclerosis, Chronic Progressive |
| D003863 | Depression |
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided
There are 3 groups (2 groups that take standard care (SC) treatment for depression will be randomized) that participants are assigned to: 1) VR plus SC therapy followed by washout and SC only; 2) SC for 8 weeks washout then VR plus SC. The third group will be VR only (not on any treatment for depression and not randomized).
Not provided
Not provided
Not provided
Not provided
|
| Standard care | Other | Participants that are in the randomized groups will continue on antidepressants or psychotherapy during the study per their standard care. Participants in the non-randomized group don't receive any treatment for their depression and will continue not to receive anything for this during the study. |
|
| Recruitment period (2 years) |
| Retention rates | Feasibility: Retention will be evaluated through the percentage of participants who complete the entire study duration, targeting a benchmark of at least 70%. | Baseline - 21 weeks |
| Adherence to VR intervention | Feasibility: Adherence to 5-15-minute sessions 3 times per week over 8 weeks | 8-week VR intervention |
| Dropout reasons | Baseline - 21 weeks |
| Hardware/software issues | During 8 weeks of VR |
| Change to the patient perceived stress scale (PSS-10) | It comprises 10 items that assess how unpredictable, uncontrollable, and overloaded respondents find their lives. Each item is rated on a 5-point Likert scale ranging from Never (0) to Very Often (4). The total score ranges from 0 to 40, with higher scores indicating greater perceived stress. While there are no established cut-off scores, higher scores suggest higher levels of perceived stress. | Baseline, 8 weeks (after VR) |
| Change in Sleep based on the Pittsburgh Sleep Quality Index (PSQI) | It comprises 19 items, generating seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each component is scored from 0 to 3, with higher scores indicating greater dysfunction. The component scores are summed to yield a global PSQI score ranging from 0 to 21. A global score greater than 5 suggests poor sleep quality. | Baseline, 8 weeks (after VR) |
| Change in the Insomnia Severity Index (ISI) | This is a brief self-report tool that evaluates the nature, severity, and impact of insomnia. It consists of seven items, each rated on a 5-point Likert scale (0 = no problem to 4 = very severe problem), assessing areas such as difficulty falling asleep, staying asleep, satisfaction with sleep, and the extent to which sleep problems interfere with daily functioning. The total score ranges from 0 to 28, with higher scores indicating more severe insomnia. Interpretation of scores is as follows: 0-7 (no clinically significant insomnia), 8-14 (subthreshold insomnia), 15-21 (moderate insomnia), and 22-28 (severe insomnia). | Baseline, 8 weeks (after VR) |
| Change in the PROMIS Fatigue | The PROMIS Fatigue Short Form 7a is a validated self-report instrument designed to assess fatigue over the past seven days. It consists of seven items that evaluate the frequency and severity of fatigue and its impact on daily activities. Each item is rated on a 5-point Likert scale ranging from "Never" (1) to "Always" (5). The raw scores are summed and converted into standardized T-scores, with a mean of 50 and a standard deviation of 10, based on the U.S. general population. Higher T-scores indicate greater fatigue severity. A change of 3 to 5 T-score points is generally considered clinically meaningful. | Baseline, 8 weeks (after VR) |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |